HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158

Benzinga · 1d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.